Sensorion has pulled the plug on its gene therapy candidate for hearing loss caused by mutations in the OTOF gene. A strategic review determined that the development environment had "notably changed," prompting the French biotech to end work on the program.
The decision stems from increased competition in the OTOF gene therapy space, with Regeneron aggressively advancing its own rival candidate. The shift marks a significant pivot for Sensorion, which had positioned the OTOF program as its lead pipeline asset.
No clinical data from the OTOF program was disclosed in the announcement, and the company has not detailed specific efficacy or safety results that may have informed the decision. The termination appears driven entirely by market and competitive dynamics rather than clinical setbacks.
Sensorion will now redirect resources toward its remaining pipeline assets, which include a gene therapy for hearing loss linked to GJB2 mutations. The company has not provided an updated timeline for these programs.
The move raises questions about the viability of smaller biotechs in niche gene therapy markets when well-capitalized competitors like Regeneron enter the fray. Sensorion shares may face pressure as investors digest the loss of the company's most advanced program.